Coral Genomics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Coral Genomics - overview
Established
2018
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded by Atray Dixit in 2018, Coral Genomics operates as a biotechnology company specializing in drug development and deployment for autoimmune diseases. The firm raised 2 grant fundings led by the National Institute of Health, in January 2021 and October 2020. The company utilizes clinical laboratory tests and data from patients to predict optimal treatment options for autoimmune diseases such as Inflammatory Bowel Disease and Rheumatoid Arthritis. By integrating molecular, functional, and clinical factors, Coral creates clinical laboratory tests that predict optimal treatment options including drug development for autoimmune diseases.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.